DeepMed Research

Gruppo Italiano Malattie EMatologiche dell'Adulto

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia, Lymphoblastic, Chronic

Interventions: Drug: Ibrutinib + ofatumumab

First Posted Date: 2015-03-13

Last Posted Date: 2025-01-29

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 19

Registration Number: NCT02388048

Locations: 🇮🇹
Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia, Ascoli Piceno, Italy
🇮🇹
Università degli Studi - Policlinico di Tor Vergata, Roma, Italy
🇮🇹
Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia, Catanzaro, Italy

and more 31 locations

Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

Completed

Conditions: Immune Thrombocytopenia

First Posted Date: 2014-11-21

Last Posted Date: 2025-04-29

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 148

Registration Number: NCT02298075

Locations: 🇮🇹
S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti, Asti, Italy
🇮🇹
Istituto di Ematologia "Lorenzo e A. Seragnoli", Bologna, Italy
🇮🇹
Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi, Catania, Italy

and more 10 locations

Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocyte Leukemia
Adult Patients

Interventions: Drug: Ibrutinib
Drug: Rituximab

First Posted Date: 2014-09-05

Last Posted Date: 2025-01-16

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 156

Registration Number: NCT02232386

Locations: 🇮🇹
Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi, Catania, Italy
🇮🇹
UO Ematologia - AOU Policlinico di Modena, Modena, Italy
🇮🇹
Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy

and more 33 locations

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Phase 1

Completed

Conditions: Complete Hematologic Remission (CHR)
Persistent/Recurrent Minimal Residual Disease (MRD)
Acute Lymphoblastic Leukemia

Interventions: Other: Autologous NK cells infusions

First Posted Date: 2014-07-10

Last Posted Date: 2023-03-30

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 6

Registration Number: NCT02185781

Locations: 🇮🇹
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, Italy
🇮🇹
Università degli Studi - Policlinico di Tor Vergata, Roma, Italy
🇮🇹
ISS/AIFA, Roma, Italy

and more 3 locations

LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients

Conditions: Chronic Myeloid Leukemia

Interventions: Other: QoL Survey Booklet

First Posted Date: 2014-06-17

Last Posted Date: 2018-08-06

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 323

Registration Number: NCT02164903

Locations: 🇮🇹
U.O. Ematologia 1 - Centro Trapianti di Midollo - Ospedale Maggiore Milano, Milano, Italy
🇮🇹
Dipartimento di Med. Clinica e Sperimentale- Area di Ematologia - Facoltà di Medicina e Chirurgia - Università degli Studi di Napoli "Federico II" -, Napoli, Italy
🇮🇹
Dipartimento di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga, Orbassano, Italy

and more 46 locations

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

Phase 2

Completed

Conditions: Untreated Philadelphia Positive Acute Lymphoblastic Leukemia
Low-dose Corticosteroids Pretreatment
De Novo
Secondary

Interventions: Drug: Prephase PDN + CY
Drug: Cycle 1 Induction
Drug: Cycle 2 Induction / Early consolidation
Drug: Cycle 3 Early consolidation
Drug: Cycle 4 Consolidation
Drug: Cycle 5 Consolidation
Drug: Cycle 6 Consolidation
Drug: Cycle 7 Consolidation
Drug: Cycle 8 Reinduction
Drug: Maintenance
Procedure: Allogeneic SCT or Autologous SCT

First Posted Date: 2014-02-20

Last Posted Date: 2021-09-08

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 204

Registration Number: NCT02067143

Locations: 🇮🇹
Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy
🇮🇹
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy

and more 57 locations

TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.

Completed

Conditions: TPO-mimetics
Adult Patients
Immune Primary Thrombocytopenia
Splenectomy

First Posted Date: 2014-02-14

Last Posted Date: 2020-10-14

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 31

Registration Number: NCT02063763

Locations: 🇮🇹
U.O.C di Ematologia P.O. "S.Giuseppe Moscati", Aversa, Italy
🇮🇹
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy
🇮🇹
UOC Ematologia Ospedale " Mons. Dimiccoli", Barletta, Italy

and more 11 locations

Occupational Status and Hematological Disease

Completed

Conditions: Chronic Thrombocytopenia
Myelodysplastic Syndrome
Hodgkin Disease
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia

Interventions: Behavioral: Study questionnaire
Behavioral: SF-36 Questionnaire

First Posted Date: 2014-02-06

Last Posted Date: 2024-02-07

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 141

Registration Number: NCT02057185

Locations: 🇮🇹
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, Italy
🇮🇹
Ospedali Riuniti "Villa Sofia-Cervello", Palermo, Italy
🇮🇹
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy

and more 3 locations

Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Antibiotic and antifungal drugs

First Posted Date: 2013-09-26

Last Posted Date: 2021-09-13

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 229

Registration Number: NCT01951430

Locations: 🇮🇹
ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO, Cagliari, Italy
🇮🇹
Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy
🇮🇹
S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy

and more 22 locations

Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia

Completed

Conditions: Acute Promyelocytic Leukemia

Interventions: Other: Health Related Quality of Life (HRQOL) measures

First Posted Date: 2013-07-29

Last Posted Date: 2014-10-02

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Registration Number: NCT01910623

Locations: 🇮🇹
Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi, Verona, Italy
🇮🇹
N. Osp. divisione di Ematologia "S.Gerardo dei Tintori!", Monza, Italy
🇮🇹
Divisione di Ematologia con trapianto di midollo - A.U. Policlinico "Paolo Giaccone", Palermo, Italy

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy